Targeted Oncology
Targeted Oncology
Targeted Oncology

Specialties

Ideal IP Chemo Approach in Ovarian Cancer Remains to be Seen

Danielle Bucco
Published Online:3:46 PM, Thu February 16, 2017

Franco M. Muggia, MD

The much anticipated initial results of the Gynecologic Oncology Group (GOG) 252 trial failed to provide additional clarity for the use of intravenous (IV) versus intraperitoneal (IP) chemotherapy in patients with ovarian cancer, explains Franco M. Muggia, MD.

In the study, approximately 1200 patients were randomized into 3 chemotherapy regimens. The reference arm consisted of IV paclitaxel at 80 mg/m2, IV carboplatin at AUC 6, and bevacizumab (Avastin) at 15 mg/kg. In the second arm, patients were treated with IV paclitaxel at 80 mg/m2, IP carboplatin at AUC 6, and 15 mg/kg of bevacizumab. Finally, the third arm included IV paclitaxel at 135 mg/m2, IP cisplatin at 75 mg/m2, IP paclitaxel at 60 mg/m2, and 15 mg/kg of bevacizumab.

Ninety percent of patients in both carboplatin arms completed a minimum of 6 cycles of platinum therapy, compared with 84% of patients in the cisplatin arm. Approximately 87% to 88% completed at least 6 cycles of the taxane in all 3 arms combined.

The primary endpoint of the study was progression-free survival (PFS). The analysis showed a median PFS of 26.8 months for patients in the IV carboplatin reference arm, 28.7 months among patients who received IP carboplatin, and 27.8 months for patients who received IP cisplatin.

In an interview with Targeted Oncology, Muggia, who is a professor of Oncology in the Department of Medicine at NYU Langone Medical Center, provided an in-depth overview of the GOG 252 trial and what the findings mean regarding IP therapy for patients with ovarian cancer.

TARGETED ONCOLOGY:  Can you give an overview of IP therapy and the GOG 252 Trial?

Muggia: This is a topic that is in transition because, since 2006, IP therapy for ovarian cancer has been standard. Unfortunately, it is associated with certain toxicities and a learning curve in terms of delivery of the treatment, so it was not applied across the board.

Some years ago, the GOG started to do pilot studies to see whether they could reduce the toxicity and retain the efficacy. Then, they devised this large study called GOG 252, for which the results of the study matured enough for PFS in March 2016. Low and behold, there is no difference between an IV arm—the former modified standard treatment—with IP cisplatin and IP paclitaxel, and a new arm to reduce toxicity of IP carboplatin with IV paclitaxel.

This trial, which accrued about 1200 patients, led to the preliminary result that would indicate no actual difference between the 3 arms. This PFS is not overall survival (OS). Typically, the OS differences in these IP versus IV trials were even greater than the magnitude of effect in PFS.

This new study had a few variables. It introduced bevacizumab across all 3 arms and that may be the reason why the PFS was increased—even in the IV arm. It also dealt with weekly IV paclitaxel during the carboplatin and in the IV arm. In 2 of the arms, there was this new modification that may have made a difference.

TARGETED ONCOLOGY:  What are the next steps, given these findings?

Muggia: We should at least switch to IP carboplatin because there are some noteworthy features of the IP carboplatin therapy. It could be just as effective, but it certainly gets rid of the toxicity, in that it comes with the other analogue cisplatin. There are 2 trials, one in Canada and one in Japan, which will look at this comparison. Therefore, we have got to get the data. In the meantime, if you want to still leverage IP chemotherapy for ovarian cancer, you should be doing IP carboplatin.

What other possibilities are there from this IP therapy? One is to focus on a certain subset of patients. We know that patients with BRCA mutations are more sensitive to the platinum drugs. They may stand to benefit the most from IP therapy and, in fact, that has been in retrospective studies from prior protocol studies. It reflects that they are the ones who benefit from the IP administration.

There were patient-reported outcomes in the 3 arms that were very well done in this last study. It showed that IV or IP carboplatin has a better quality of life than IP cisplatin. This is no surprise to people who use the drugs but, in the IP studies in the past, the control was IV cisplatin.

Now, the control in this last study was IV carboplatin and so there is an even greater contrast that the quality of life for the IP chemotherapy may be impacted upon. Therefore, it’s incumbent that we make the proper modifications to make it just as effective, which it seems to be. It may be that the spotlight is on IP carboplatin. We'll be in limbo for another year until these studies mature.

TARGETED ONCOLOGY:  Are researchers looking at any other interesting combinations?

Muggia: There are a couple of studies going in that direction, where people have looked at various combinations. There is a study done by the GOG that is comprised of platinum-resistant patients receiving IP carboplatin with IP bortezomib (Velcade). Bortezomib is a proteasome inhibitor that interferes with the degradation of the transporter. When platinum therapy hits the transporter, it gets internalized and degraded, so no more platinum gets transported in. If you interfere with that transport degradation, you keep transporting platinum—and that was the hypothesis. Sure enough, in this small study of 20 patients or so, there were quite a few responses in this protocol.
 
 
Reference:
Walker JL, Brady MF, DiSilvestro PA, et al. A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma NCI-supplied agent(s): bevacizumab (NSC #704865, IND #7921) NCT01167712 a GOG/NRG trial (GOG 252). Presented at: 2016 SGO Annual Meeting. March 19-22, 2016. San Diego, CA. Late-breaking abstract.


Publications